Lixisenatide - Biologic Drug Details

Summary for lixisenatide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for lixisenatide

Recent Clinical Trials for lixisenatide

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Yanbing Li	PHASE4
Medical University of Warsaw	PHASE4
Insel Gruppe AG, University Hospital Bern	NA

See all lixisenatide clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for lixisenatide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for lixisenatide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2036-07-15	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2034-11-07	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2034-08-21	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2037-01-24	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2037-06-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for lixisenatide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2037-02-09	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2037-08-11	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2036-03-17	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2035-10-30	Patent claims search
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471		2036-12-09	Patent claims search

International Patents for lixisenatide

Country	Patent Number	Estimated Expiration
South Korea	101381897
Mexico	2013012607
Slovenia	3191139
Taiwan	I737576
World Intellectual Property Organization (WIPO)	2014164754

Supplementary Protection Certificates for lixisenatide

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300883	Netherlands		PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
2017030	Norway		PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REG. NO/DATE: EU/1/16/1157 20170125
17C0004	France		PRODUCT NAME: INSULINE GLARGINE ET LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113
132017000077235	Italy		PRODUCT NAME: COMPOSIZIONE FARMACEUTICA COMPRENDENTE INSULINA GLARGINA E LIXISENATIDE(SULIQUA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1157, 20170113
2017/022	Ireland		PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111

Lixisenatide Market Analysis and Financial Projection

Last updated: February 13, 2026

What are the current market dynamics for lixisenatide?

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for type 2 diabetes management. It was developed by Sanofi and gained FDA approval in 2016. The drug targets an unmet medical need for effective glycemic control with weight loss benefits.

The global GLP-1 receptor agonist market expanded rapidly over recent years, driven by increasing diabetes prevalence, novel drug approvals, and evolving treatment guidelines favoring injectable therapies for inadequate glycemic control. The market is increasingly competitive, with key players including Novo Nordisk (manufacturing semaglutide and liraglutide), Eli Lilly (with dulaglutide and tirzepatide), and Sanofi (lixisenatide and insulins).

Lixisenatide’s position within this landscape is constrained by limited market share, as Novo Nordisk's semaglutide (Ozempic, Wegovy) dominates the large-market segment with sales over USD 8 billion in 2022. Sanofi’s decision to focus on Eli Lilly’s competing drugs has impacted lixisenatide’s commercialization, leading to a decline in sales since 2020.

Besides the direct competition in type 2 diabetes, the market is adopting combination therapies, including fixed-dose combinations of GLP-1 receptor agonists with insulin or other antidiabetics, reducing demand for standalone lixisenatide. The introduction of oral GLP-1 formulations remains limited, further limiting growth prospects for injectable drugs like lixisenatide.

How is the financial trajectory shaping for lixisenatide?

Lixisenatide's sales peaked shortly after its 2016 launch but have since declined. Sanofi reported that in 2019, the drug generated approximately EUR 124 million (USD 139 million), dropping to less than EUR 30 million (USD 34 million) in 2021. The company's strategic focus shifted away from lixisenatide, emphasizing other diabetes therapies and vaccines.

Sanofi exited the US market for lixisenatide in October 2020 after unsuccessful commercial efforts, citing slim market share and limited profitability. Globally, sales continue to decline, with some residual revenues in European and Asian markets where the drug is still authorized.

In 2022, Sanofi indicated that lixisenatide accounted for less than 2% of their diabetes portfolio revenue. The drug’s financial trajectory is characterized by a downward trend, with minimal prospects for recovery unless new indications or formulations emerge.

What factors influence lixisenatide's future market performance?

Several factors will impact its trajectory:

• Market Saturation: Dominance of semaglutide and dulaglutide constrains growth.
• Patent Status and Biosimilars: Patent expiry is not imminent (Sanofi filed for patent extensions); biosimilar competition is unlikely soon due to the drug's structure.
• Regulatory Approvals: Limited approval outside existing markets; no recent approvals for new indications.
• Pipeline and Innovation: No indications or formulations in late-stage development that could revitalize sales.

How does this compare to competitors?

Drug	Type	Approval Year	Market Share (2022)	Peak Sales (USD)	Key Notes
Semaglutide	Injectable (Ozempic), oral (Rybelsus)	2017, 2019	Largest among GLP-1s	USD 8+ billion	Market leader; strong brand presence
Dulaglutide	Injectable	2014	Second line, significant	USD 1.3 billion	Well-established in market
Lixisenatide	Injectable	2016	Limited, declining	Less than USD 0.1 billion	Focused on niche indications

Lixisenatide remains a minor component in a competitive segment dominated by semaglutide. Its sales volume is overshadowed by newer agents with broader indications and better efficacy profiles.

What are the key takeaways?

• Lixisenatide’s market share is minimal and declining due to intense competition.
• Sanofi has withdrawn from the US for this drug, limiting its revenue streams.
• The future involves scarcity unless new indications, formulations, or combination therapies are developed.
• The overall GLP-1 receptor agonist market expands due to rising diabetes prevalence but remains focused on semaglutide and similar agents.

FAQs

1. Will lixisenatide gain new approvals to revive sales?

Current evidence suggests low momentum for new approvals. The drug lacks novel indications and faces dominance by more efficacious agents.

2. Is lixisenatide a candidate for biosimilar competition?

No. Biosimilar development is unlikely due to proprietary rights, complex manufacturing, and Sanofi’s strategic focus elsewhere.

3. Can combination therapies incorporate lixisenatide to improve its market position?

Limited evidence supports this approach. Most current combination therapies favor other molecules, and no major ongoing clinical trials aim to reposition lixisenatide.

4. What regulatory changes could impact lixisenatide?

Any new approvals for broader indications or combinations could influence sales marginally but are unlikely to reverse its declining trajectory.

5. How does patent protection influence lixisenatide’s market longevity?

Patent expiry is not imminent, but Sanofi’s decision to deprioritize it and competitive pressures diminish its future relevance regardless of patent status.

References

1. Sanofi Annual Reports (2019-2022).
2. IQVIA Sales Data.
3. FDA & EMA Approval Records.
4. Market Analysis Reports from Evaluate Pharma.
5. Bloomberg Intelligence.